NextCure (NXTC) investor relations material

Introduction and agenda

• Event focused on preliminary Phase 1 trial results for SIM0505, a CDH6-targeting ADC, presented at or after ASCO 2026, with agenda covering differentiation, clinical data, unmet needs, and Q&A.

• Virtual KOL event scheduled for June 2, 2026, to discuss positive Phase 1 SIM0505 data in gynecologic cancers, with replay available for 90 days.

KOL background and credentials

• Dr. Rakesh Dixit: ADC expert and scientific advisory board member, developed several approved agents.

• Dr. Ursula Matulonis: Chief of Gynecologic Oncology at Dana-Farber, led landmark ovarian cancer trials.

• Dr. Beryl Manning-Geist: Assistant Professor at Emory, clinical investigator for SIM0505, focuses on underserved populations.

• Udayan Guha, MD, PhD, Chief Medical Officer, highlighted clinical significance and safety profile.

• Speakers included CEO, CMO, ADC specialist, and leading gynecologic oncology experts from Dana Farber and Emory University.

Market insights and analysis

• Platinum-resistant ovarian cancer and uterine serous carcinoma have significant unmet needs, poor outcomes, and high mortality.

• Ovarian cancer is the fifth leading cause of cancer-related death among women, with late-stage diagnosis common and a 5-year survival rate of 51.6%.

• Uterine serous carcinoma, though only 10% of uterine cancers, causes 40% of deaths, with most patients diagnosed at advanced stages.

• SIM0505 targets CDH6, highly expressed in multiple solid tumors, offering a promising new approach.

• Current treatments for these cancers yield low response rates, especially after multiple prior therapies.